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Primaquine was firstly synthesized in 1946 in the USA, and is the most representative member of the
anti-malarial 8-aminoquinolines. Six decades have passed and primaquine is still the only trans-
mission-blocking anti-malarial clinically available, displaying a marked activity against gametocytes of
all species of human malaria, including multi-resistant Plasmodium falciparum strains. Primaquine is
also effective against all exoerythrocytic forms of the parasite and is used in conjunction with other
anti-malarials for the treatment of vivax and ovale malaria. However, primaquine is often associated
with serious adverse effects, in consequence of its toxic metabolites. 5-Hydroxyprimaquine or 6-
methoxy-8-aminoquinoline has been considered to be directly responsible for complications such as
hemolytic anemia. Primaquine toxicity is aggravated in people deficient of 6-glucose phosphate
dehydrogenase or glutathione synthetase. Adverse effects are further amplified by the fact that pri-
maquine must be repeatedly administered at high doses, due to its limited oral bioavailability. Over the
last two decades, Medicinal Chemists have battled against primaquine’s disadvantages, while keeping
or even improving its unequalled performance as an anti-malarial. The present text revisits primaquine
and its properties on the occasion of its 60th anniversary and aims to give a general overview of what
has been the path towards the development of effective and safe primaquine-based anti-malarials.
Presently, aablaquine and tafenoquine the two most promising primaquine analogues are already in the
final stages of clinical trials against Plasmodium vivax and P. falciparum. Both compounds are a new hope
against malaria and other primaquine-sensitive illnesses, such as Pneumocystis Pneumonia or the
Chagas disease.
 2008 Elsevier Masson SAS. All rights reserved.1. Primaquine revisited
1.1. Historical synopsis
Tropical diseases, normally confined to underdeveloped
regions of the globe, have been traditionally neglected by the
pharmaceutical industries and, consequently, seldom considered
as hot matter capable of drawing the attention of top scientists,
from chemists to physicians. This attitude was changed by force of
historical events in some periods, such as the first half of the 20th
century, when world-wide belligerency required western soldiers,
fighting in tropical regions, to be protected against this epidemics
[1,2]. Consequently, in the 30 years’ gap between the middle of
World War I and the end of World War II was examined a huge: þ351 220402659.
son SAS. All rights reserved.number of potential anti-malarial drugs, over 12 000 of which
were 8-aminoquinolines (8AQ) [3]. One of the first anti-malarial
8AQs, known as pamaquine or plasmochin (1), was synthesised in
1925 and was able to destroy the parasite’s gametocytes when
used in combination with quinine. This was useful for the
prevention of relapses associated to the Plasmodium vivax infection
[4], but pamaquine showed little effectiveness against blood-
induced infection, i.e., it was a poor blood-schizontocide. But the
greatest disadvantage of this drug was its high toxicity that ulti-
mately led to the abandonment of its therapeutic use [5].
Notwithstanding, pamaquine represented the stepping-stone for
the development of safer anti-malarial 8AQs that culminated, in
1946, in the synthesis of the 8AQ SN-13,272 by Elderfield and co-
workers, in the United States of America [6]. This compound,
named primaquine (PQ, 2), was successfully tested in WWII pris-
oners, American volunteers and American soldiers fighting in
regions like Korea [6]. Other anti-malarial 8AQs, such as penta-
quine or isopentaquine [7–9], also appeared in the 1940s, but PQ
was the one presenting the highest efficacy and the lowest toxicity
levels.
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Table 1
PQ-based therapeutic approaches against vivax and ovale malarias
Therapeutic approach Description
Primary prophylaxis Prevents primary installation of parasitemia, in
opposition to terminal prophylaxis that prevents
relapse (see below).
A daily 30 mg dose (adult) is used and the
administration begins one day before the risk of
exposition, i.e., arrival to a malaria-endemic region,
and is prolonged for 1 week after departure from that
region. For children and adults under 60 kg of weight,
the recommended dose is 0.5 mg/kg/d [14].
Terminal prophylaxis
or PART
Presumptive anti-relapse therapy (or terminal prophy-
laxis) uses medications towards the end of the exposure
period (or immediately thereafter) to prevent relapses
or delayed-onset clinical presentations of malaria
caused by hypnozoites (dormant liver stages) of P. vivax
or P. ovale [14].
PQ is used in conjugation with a schizontocide
(chloroquine, mefloquine, doxycycline) at a recom-
mended daily dose of 15 mg PQ during 14 days
(adults). However, full elimination of hypnozoites of
some P. vivax strains requires an increase of the daily
dose to 30 mg. Similarly, the paediatric doses can be
increased from 0.25 to 0.5 mg/kg/d, according to the
parasite strain that prevails at the site of exposure. The
beginning of terminal prophylaxis with PQ should
coincide with the last 2 weeks of prophylactic admin-
istration of schizontoxides doxycycline, mefloquine or
chloroquine or with the final week of prophylaxis with
atovaquone–proguanil [14,19,20].
Radical cure PQ is administered together with a blood-schizontocide
(e.g., chloroquine) for complete cure of installed P. vivax
and P. ovale infections with the advantage that PQ can
prevent relapses due to hypnozoites of both strains, as
described above. Recommended PQ dosage is the same
as described for terminal prophylaxis [14,21–23].
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the employment of PQ, primarily as a transmission-blocking anti-
malarial (gametocytocide) but also as a tissue-schizontocide, as
well as of chloroquine (CQ), a potent blood–schizontocidal 4-ami-
noquinoline (4AQ), also effective against the most lethal Plasmo-
dium falciparum strains [10]. This, and the use of DDT against the
mosquito vectors, led to the eradication of malaria from tempered
and sub-tropical regions of the globe by the early 1960s, which
cooled the interest of developed countries in continuing the search
for improved anti-malarials, even though some problems associ-
ated with current therapies were already being identified in
endemic areas like Sub-Saharan Africa [10]. Some of these prob-
lems included the aggravated hematotoxicity of PQ in humans
deficient in 6-glucose phosphate dehydrogenase (6GPD), a genetic
condition frequent among African men, and the development of
general resistance of P. falciparum against CQ [10]. Again, these
problems were mainly restricted to tropical countries and did not
captivate the interest of either thewestern pharmaceutical industry
or the scientific community until the 1980s, when some cases of
malaria were registered in sub-tropical and tempered areas [11]
‘‘Imported malaria’’ is presently a serious risk world-wide due to
both increased people’s migration or tourism-related mobility and
global warming. It is a top-priority disease and composes theWHOs
‘‘big-three’’ together with tuberculosis and AIDS [11]. This sprang
a new search for more active and safer anti-malarials over the last
two decades, much of it inspired in PQ and related 8-amino-
quinolines [12,13].
1.2. A snapshot of PQ’s therapeutic profile
1.2.1. Against malaria: use, limitations and search for alternative
administration strategies
PQ is useful to fight malaria on three different fronts: (i) primary
prophylaxis against all species of malaria, (ii) presumptive anti-
relapse therapy (terminal prophylaxis) for persons extensively
exposed to P. vivax or Plasmodium ovale, (iii) radical cure in indi-
viduals infected with P. vivax or P. ovale [14]. In endemic regions, PQ
is used as a gametocytocide to prevent the transmission of the
infection from the human host to the mosquitoes, thus blocking the
spread of the disease [15].
Normally, a total of 200 mg dose of PQ (as the free
basez 350 mg of the phosphate salt) leads to a full cure. The
regimen usually adopted and generally well-tolerated is 15 mg per
day over 14 days [9,14]. Table 1 summarises the different PQ-based
therapeutic approaches, according to the acuteness of the infection.
PQ is contraindicated for children under 4 years old and its
administration requires a previous test for glucose-6-phosphate
activity (G6PD) in the patient [16]. PQ is not suitable to be used as
a single drug to treat malaria, as it is not effective against endo-
erythrocytic forms of Plasmodia, thus must be co-administered
with blood-schizontocides [9].
The reappearance of malaria vivax in certain regions of the
world by the end of the 20th century reinforced the relevance andthe need of finding more effective treatments for the disease. An
inadequate attack on the hypnozoite reservoir of infection can
contribute to the aggravation of malaria. Ideally, PQ should be
a well-tolerated drug and a totally safe drug of easy administration,
so it could be employed at higher doses without risk for the patient
(cf. Section 2). However, further from the aforementioned problems
related to PQ-based therapies, PQ is not prescribed during preg-
nancy because of the risk of intravascular hemolysis in the mother
and fetus [17]. Recently, changes in the platelet count and lipid
parameters are reported for malarial patients after treatment with
hydroxychloroquine and PQ for acute P. vivax malaria [18].
To circumvent problems associated with PQ, some researchers
have proposed high-dosages over short administration periods,
whereas others have recommended the use of quinine while
assessing the efficacy of PQ at either standard or experimental PQ
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liver and may produce undesirable outcomes if administered over
long time periods [25].
PQ is also characterized by low plasma half-lives, which require
frequent administration and amplify its adverse effects (cf. Section
2). To reduce these effects and increase the efficacy of treatment,
some researchers have suggested different routes of PQ adminis-
tration, such as transdermal therapeutic systems (TTS), encapsu-
lation in nanoparticles or liposomes, and emulsification.
One example of the TTS approach is the work by Mayorga et al.
who established an ethyl cellulose-based TTS formulation that was
shown to be viable and bring advantages for transdermal delivery
of PQ [26]. Thus, PQ presented high flow in vitro from aMiglyol 840
(M840) TTS across hairless rat skin; recent studies indicated
extensive binding to corneocyte keratin with significant effect on
reservoir formation and on the permeability of PQ across human
skin [27].
Galactose-coated polypropyleneimine (PPI) nanoparticles were
tested as PQ vehicles and were found to have drug entrapment
efficiency 5–15 times higher than that of uncoated PPI. Galactose
coating prolonged release up to 5–6 days as compared to 1–2 days
for uncoated PPI systems [28]. PQ has also been conjugated to
periodate-oxidized Gum Arabic through the drug’s amino groups,
which allowed obtaining microspheres too small to be attacked by
macrophages [29,30].
Nebulization of an aqueous mixture of PQ diphosphate and
albumin into heated vegetable oil was used to produce micro-
spheres with an average size of 6 mm. These microparticles were
relatively stable in buffer at pH 7.2 and 4.5, while being completely
degraded by proteolytic enzymes such as trypsin. Pharmacokinetic
studies suggested the microparticles to accumulate in liver
showing sustained release of PQ for at least 48 h post-administra-
tion [31].
Thepreparationof PQ-loaded-poly (D,L-lactide) nanoparticleswas
reported as well. Intravenously injected PQ-loaded nanoparticles
were well-tolerated by healthy and Leishmania donovani-infected
mice. The 50% lethal dose of primaquine-loaded nanoparticles was
significantly reduced when compared to that of free PQ [32].
PQ was also incorporated into oral lipid nanoemulsions having
particle sizes in the range of 10–200 nm. The emulsions showed
effective anti-malarial activity against Plasmodium berghei infection
in Swiss albino mice at 25% lower dose levels as compared to the
conventional oral dose. Lipid nanoemulsions of PQ exhibited
improved oral bioavailability and were taken up preferentially by
the liver with drug concentrations higher at least by 45% as
compared to the plain drug [33].
PQ has been successfully encapsulated in liposomes in response
to a pH gradient. The efficacy of PQ encapsulation depended on the
lipids that composed the vesicles and, consequently, on liposome
charge and presence of cholesterol, on the buffer internal capacity
and on the drug-to-lipid ratio and/or incubation time [34].
Finally, additional studies where PQ was incorporated in
emulsions have shown the drug to be more stable when emulsified
than when given as the free compound incubated in serum. When
intravenously injected into mice, the chylomicron emulsions con-
taining PQ led to an increased accumulation of PQ in liver, as
compared to injection of free PQ [35].
Notwithstanding, none of the above alternative routes for PQ
administration have stepped forward to clinical applications.
1.2.2. Against pneumocystic pneumonia
Pneumocystis jiroveci is a fungus that contacts innocuously with
healthy lungs, but causes pneumocystic pneumonia (PCP) in indi-
viduals with weakened immune systems, such as patients with
cancer or under anti-cancer treatments, patients submitted to
organ transplantation or HIV-infected individuals. PCP is often thefirst indicator of HIV-infection and over 80% of patients with AIDS
that have not received a buffer prophylaxis end up developing PCP
at any moment, which leads to a fast degradation of their health
condition and quality of life and, ultimately, to death [36–39].
PQ is useful against PCP, both for prophylaxis and for treatment,
when given in combinationwith clindamycin (CM, 3). PQ interferes
with the microbial electron transport system by yielding quinone
metabolites that generate superoxides in vivo [40]. The PQ–CM
approach is employed for the treatment of moderate PCP or as
salvage therapy [42–49]. The effective daily dose for PCP treatment
is 2 mg/kg of PQ and 225 mg/kg of CM. Lower doses are applied for
prophylaxis [40].
So far, the first-line therapy against PCP is the trimethoprim–
sulfamethoxazole antifolate combination found in Bactrim or
Septra. However, there is a high frequency of development of
severe intolerance to the sulfa component among patients with
AIDS [48]. This justifies the need for alternative therapies such as
PQ–CM, even though this approach has itself some complications
due to PQ-associated toxicity, the main of which is anemia [44].
Therefore, other PQ analogues or derivatives have been explored as
anti-PCP agents [43,45,46].1.2.3. Against leishmaniasis
Leishmaniasis affects mostly canines but can be transmitted to
humans. It is caused by different species of a protozoan belonging
to the Leishmania genus. Humans are mainly affected by three
forms of Leishmania: Leishmania cutanea, Leishmania mucocutanea
and Leishmania visceral. Typically, patients with visceral leish-
maniasis present fever, cough, abdominal pain, diarrhoea, epistaxis,
spleenomegaly, hematomegaly, cachexia and pancytopenia [49].
Even though PQ has no clinical application against leishmani-
asis, it exhibits leishmanicidal activity in vitro [50]. Some deriva-
tives of PQ, especially 6-desmethyl-8-aminoquinolines, have been
generally more active in vitro than the parent drug against
macrophage-contained Leishmania [50]. Recently, Kaur et al. pre-
sented several biological studies focused on 8AQs and confirmed
that PQ has leishmanicidal activity in vitro, but with IC50 values
(w20 mg/mL) superior to those of reference drugs in leishmaniasis
therapy, such as pentamidine (IC50¼1 mg/mL) or amphotericin B
(IC50¼ 0.19 mg/mL) [51]. PQ also showed in vitro leishmanicidal
properties when encapsulated in liposomes, against parasite-
infected macrophages [52].
Despite the lack of prominence of PQ in this therapeutic area,
many related 8AQs are exhibiting promising results. The relevant
examples are those of two anti-malarial compounds, NPC 1161 [53]
and, especially, sitamaquine that is already in an advanced phase of
clinical trials (see Section 4.3) [54–56].
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Chagas disease (American trypanosomiasis) is a zoonosis caused
by the flagellate protozoan parasite Trypanosoma cruzi and affects
approximately 18 million people in Central and South America [57].
PQ is not clinically used for the therapy of Chagas disease.
However, both PQ and its 2-methyl-PQ derivative were reported to
be almost four times as effective as the control drug, nifurtimox,
against the model disease in mice [58]. One of the hypotheses that
advanced for the anti-trypanosomiasis activity of PQ and related
8AQs relies on themetabolic formation of free radicals that increase
the oxidative stress in T. cruzi [59].
Experiments were designed to evaluate the relative activity of
PQ against extra- and intracellular T. cruzi and to determine
whether this drug should be combined with ketoconazole (4), an
antifungal imidazole and potent CYP3A4 inhibitor [60]. The
combination of PQ with ketoconazole, administered to acutely
infected mice, significantly decreased parasitemias in comparison
to treatment with PQ or ketoconazole alone [61].NN
O
O
O
O
N
N
Cl
Cl
41.2.5. Against other diseases
PQ and related drugs have seldom been studied as potentially
useful against diseases other than those above indicated. However,
some isolated reports can be found, such as the study, in 1974, of
the effect of PQ against viral replication in Newcastle disease. This
study was carried out in chicken embryo cells and showed that
virus-induced hemadsorption was completely inhibited by 250 mg
of PQ/mL [62].
Also, a series of experiments were conducted to investigate the
anticoccidial activity of pamaquine and PQ, against laboratory
strains of Eimeria tenella, Eimeria necatrix, Eimeria acervulina,
Eimeria maxima and Eimeria brunette, revealing that both drugs
were effective against E. tenella and E. necatrix, but not against the
other three species [63]. The anticoccidial activity of PQ has also
been tested by Armer et al. who found that both PQ and pamaquine
possess in vivo anticoccidial activity in broilers against the proto-
zoan parasites E. tenella and E. necatrix [64,65]. These authors
established that the drugs are not active themselves against Eime-
ria, but generate active metabolites in vivo, thus actuating as
prodrugs.
1.3. PQ combined with other drugs
There are several arguments for the use of combinations of
drugs for the treatment of disease, the main of which is based on
simultaneous attack to different biological targets that are vital to
the pathogen [66]. PQ-based therapies are no exception.
The combination of PQ with chloroquine (CQ) was used in the
Korea War (1950–1953) by American soldiers infected with
relapsing P. vivaxmalaria. This combination was commercialized in
tablets under the name of ‘CP’. Each tablet contained 300 mg of CQ
and 45 mg of PQ and was administered following repatriation once
weekly for 8 consecutive weeks. ‘CP’ was abandoned when para-
site’s, especially P. falciparum’s, resistance to CQwas detected in the1960’s. Notwithstanding, CQþ PQ combinations have a role against
both tissue and blood-schizontocides that are to be deployed in
endemic areas [67]. CQ, sulfadoxine/pyrimethamine and PQ were
combined together in an early work, and while no effect on asexual
stage parasitemia was apparent, clearance of gametocytes was
significantly accelerated [68]. Bray et al. analysed matched trans-
fectants expressing mutant and wild-type alleles of the P. falcipa-
rum chloroquine resistance transporter (PfCRT) and concluded that
PQ exerts its activity by blocking PfCRT, thus enhancing accumu-
lation of CQ [69]. Moreover, the alternative administration of PQ
and CQ sequentially instead of simultaneously is clinically viable,
and may constitute a cost-effective way of treating CQ-resistant
malaria [70].
Co-administration of mirincamycin (2.5 mg/kg) with PQ was
seen to exert a significant reduction in the dose of PQ required for
cure of established infections with sporozoites of Plasmodium
cynomolgi. This effect was further seen to be inversely related to the
size of the sporozoite inoculum [71].
Quinine has no significant effect on the kinetics of PQ but
a decrease in Cmax of carboxyprimaquine was observed after co-
administrationwith quinine. The interaction of PQwithmefloquine
was also investigated in human liver microsomes and it appeared
that metabolism of mefloquine was somewhat retarded by PQ.
However, co-administration of PQ did not affect the pharmacoki-
netics of mefloquine in vivo. On the other hand, in vitro studies
have shown that PQ conversion into carboxyprimaquine is inhibi-
ted by ketoconazole (4) [72].
Last, but not least, PQ combinations with artemisinin derivatives
also seem interesting. Artesunate reduced the appearance of
gametocytemia in adult Thai patients infected with uncomplicated
P. falciparum malaria, whereas its combination with PQ resulted in
shorter gametocyte clearance times [73]. In other study, the
combination of 5 days of artesunate and 14 days of PQ was found to
be a highly effective and generally well-tolerated treatment
regimen for vivax malaria in Thailand [74].
1.4. Primaquine in the body
1.4.1. A yet unveiled mechanism of action
The exact mechanism by which PQ so effectively eliminates
Plasmodia hypnozoites and gametocytes is still unknown, but it is
thought that metabolism at the parasites’ mitochondria is
impaired, eventually by interference with the ubiquinone function
as an electron carrier in the respiratory chain [75]. Another
potential mechanism of anti-malarial action by PQ is the produc-
tion of highly reactive metabolites (cf. Section 2) that generate
intracellular oxidative potentials [14]. Biotransformation of 8AQ
seems to be necessary for their toxicity as well as efficacy. Selective
generation of oxidative stress in the parasitized cells is the most
plausible mechanism for 8AQ toxicity and efficacy [76].
While the mechanism of action of 4AQ (as chloroquine) is
believed to be based on detoxification of hematin in the parasite’s
food vacuole (FV) that of 8AQs remain unclear. When the 4AQ drug
reaches the proton-rich FV, it accumulates due to the local pH;
there it binds to hematin, whose accumulation in the FV leads to
the death of the parasite [10,77–80]. In turn, how and why PQ and
related 8AQs specifically act against certain stages of the parasite’s
life cycle is still a matter of debate. During the third morphological
stage of P. falciparum gametocyte formation (Fig. 1), macro-
gametocytes begin to show a marked increase in cristate mito-
chondria [81]. Normally, late-stage gametocytes (stages IV–V in
Fig. 1) are more resistant to anti-malarial drugs [82] and metabolic
inhibitors [83] than are early-stage gametocytes or asexual forms of
the parasite. PQ is the one drug towhich the late-stage gametocytes
are more sensitive than asexual stages. Selective accumulation of
tritiated PQ (3H-PQ) in Plasmodium mitochondria was seen to
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Fig. 1. The life cycle of Plasmodium falciparum. Adapted from Ref. [83].
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tissue stages of Plasmodium fallax [84]. Other studies indicate that it
causes mitochondrial swelling in several Plasmodium strains and
stages [85–87], including P. falciparum gametocytes [88]. Additional
reports suggest that exposure to PQ affects mitochondrial prolif-
eration and inhibits growth on development stages that require
functional mitochondria [87,89–93].
Irrespective of the specific underlying biochemical mechanisms,
it is undeniable that metabolically senescent stages of Plasmodia
are sensitive to 8AQs. Evidence of mitochondrial ultrastructure
changes in P. falciparum when exposed to 8AQs reinforces that
these may be related to the biochemical changes in the mito-
chondria-directed metabolic activity of the parasite [81]. Alterna-
tively, the lack of biochemical mechanisms in the parasite suitable
to eliminate PQ or its metabolites, as well as stage-specific inability
to copewith oxidative stress,may account for both the lowparasitic
resistance against PQ and its specificity against certain stages of the
parasite’s life cycle [94].
Bapiro and co-workers investigated the inductive effects of 24
antiparasitic drugs on the enzymatic activity of cytochromes P450
(CYP) 1A1 and 1A2 [95]. These authors used human hepatoma
(HepG2) cells that were exposed to the test drugs, after which the
ethoxyresorufin-O-deethylase (EROD) activity was evaluated as
a measure of CYP1A enzyme activity. In the human body, PQ did not
cause a significant induction at concentrations typically found in
plasma (w0.4 mM) and the authors concluded that induction of
CYP1A1/2 activity by PQ was not of any pharmaceutical or toxico-
logical significance [95].
Studies in vitro by Olenick and Hahn with Bacillus megaterium
suggested that the main route by which PQ acts against this
bacterium is by the blockage of protein synthesis [96]. The same
authors reported 3 years later that PQ inhibited polyphenylalaninesynthesis directed by poly(U) in cell-free systems obtained from
B. megaterium, when the drug was pre-incubated with ribosomes,
poly(U) or tRNA [97]. However, so far there is no evidence that
impairing of plasmodial protein synthesis lies behind the anti-
malarial action of PQ.
As PQ has a stereogenic centre, it would be expectable that
each isomer had different activities, considering the most prob-
able involvement of enzymes in the drug’s mechanism of action.
Many scientists defended that PQ isomers have similar activity,
based on the fact that both presented identical capacity for the
radical cure of rhesus monkeys infected with sporozoites of
P. cynomolgi [98]. Studies in mice indicated that the subacute
toxicity of l-PQ is 3–5 times higher than that of d-PQ and 2 times
less than PQ. The acute single-dose toxicity of the d-PQ was at
least 4 times as toxic as l-PQ [98,99]. It is noteworthy that PQ is
not a racemic mixture, because l isomer prevails over the
d isomers. When racemic PQ was administered to rats, the
majority of the residual PQ excreted in urine was found to be
the (þ)-isomer [100]. Agarwal et al. studied in vitro the effects of
PQ enantiomers and observed that a 1.5 mM concentration of
()-PQ produced a significantly greater increase in methemoglo-
binemia (MetHb) content and decrease in reduced glutathione
(GSH) levels than did (þ)-PQ. However, the release of plasma
hemoglobin was greater with (þ)-PQ than with ()-PQ [101]. On
the whole, it is clear that PQ biotransformations behind both its
toxicity and its anti-malarial action involve chiral recognition,
even though exact mechanisms are not yet established.
The in vivo skin absorption profile of PQ was also investigated
through employment of a TTS based on ethyl cellulose polymer,
indicating controlled and systemic delivery of the drug over
a period of 40 h [102]. The permeation of PQ across full-thickness
excised human skin from two acrylate transdermal adhesives was
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adhesive patch formulation incorporating PQ can deliver suitable
doses to provide new treatment and prophylaxis regimens for P.
vivax and P. ovale malaria [103].
1.4.2. Other biological effects of PQ
PQwas found to be an inhibitor of vesicular transport and blocks
the calcium-release-activated current (Icrac) in rat megakaryocytes,
i.e., PQ blocks the appearance of Ca2þ influx currents in response to
Ca2þ store depletion in rat. PQ is less effective if added after Icrac had
developed. The channels underlying Icracmay be held in amembrane
compartment and transport to theplasmamembrane follows release
of internal Ca2þ [104]. The role of membrane fusion in the activation
of store-activated Ca2þ channels (SACCs) in plasma membrane of
oocytes in Xenopus laeviswas investigated in the presence of PQ. The
results indicate that PQ affects the opening of SACCs by direct inhi-
bition of Ca2þ flux through the channel pores [105].
PQ also acts on cardiac Naþ channels, according to another
researchwork where the electrophysiological effects of PQ on those
channels were examined in isolated rat ventricular muscle and
myocytes. PQ was found to block the cardiac channels with high
affinity, exhibiting high selectivity for the Naþ channel blockade in
comparison to the blockade of the Kþ cardiac channel [106].
Protein transport is affected by PQ at a half-maximal concen-
tration of 50 mM and morphological data indicate that the drug
inhibits the budding of vesicles from the donor membranes. After
their formation, the vesicles are refractive to PQ action, so their
attachment and subsequent fusion with an acceptor membrane
proceed normally [107]. Also, insertion of pre-formed fibrosis
transmembrane conductance regulator (CFTR) into the plasma
membrane could be prevented by compounds that interfere with
intracellular transport mechanisms such as PQ [108].
The weakly basic character of PQ leads to its accumulation in
endosomes in its protonated form and, consequently, it modifies
the endosomal pH. Further, PQ has a strong inhibitory effect on the
recycling of endocytosed proteins to the plasma membrane [109].
This inhibitory effect of PQ may be due to the interference with
calmodulin function at endosomes. PQ inhibited Ca2þ/calmodulin-
dependent kinase II (CaM-kinase II) activity with maximal inhibi-
tion at 1 mM, consistent with the idea that the crucial factor behind
PQ interference with membrane protein recycling could be modi-
fication of calmodulin activity [110].
Several anti-malarial agents inhibit diverse types of voltage-
gated ionic channels [111–113], as well as acetylcholine (Ach)
receptors that operate in potassium current (IKAch) through musca-
rinic potassium channels, alone or linked to GTP-proteins (guano-
sine-50-triphosphate-linked proteins) [111]. Distinct anti-malarials
may exhibit anticholinergic activity via different molecular mecha-
nisms; PQ and quinidine inhibit the potassium current by blockade
of muscarinic receptors [111]. In an early study, the capacity of some
anti-malarials, including PQ, to inhibit human erythrocyte
membrane acetylcholinesterase (AChE) and the mechanism under-
lying their inhibitory action were evaluated [114]. This study
revealed that all tested drugs were potent inhibitors of human AChE
but had distinct inhibitory capacities. In the case of PQ, the
concentration requested to obtain 33% of inhibition (IC33) was 30 mM
[114].
Michihara et al. reported the effects of PQ on lysosomal integrity
in cultured rat hepatocytes and the percentage of lysosomal
disruption in living cells at 50 mM and 100 mM of drug to be 1% and
4%, respectively. Additionally, levels of lysosomal disruption upon
homogenization or centrifugation during cell fraction at those two
concentrations of PQ were 2% and 7%, respectively [115].
Finally, the mutagenic activity and mutational specificity of PQ
were studied after pre-treatment with nitrite on Escherichia coli
and Salmonella typhimurium. The drug was mutagenic in bothmicrobial strains, suggesting that PQ is a nitrite-reacting mutagen
precursor where the secondary amino group plays a key role [116].2. Drawbacks in PQ-based therapies
2.1. Parasitic resistance
The establishment that parasitic resistance is occurring requires
the demonstration that parasites are able to survive in vivo in the
presence of an adequate therapeutic concentration of the drug
system [117]. Several anti-malarial drugs are referenced as affected
by the problem of resistance by Plasmodia, among which chloro-
quine is known to present severe resistance problems from both
the deadliest P. falciparum and the second most concerning P. vivax
strains [118–120].
The resistance to PQ is incredibly low, hardly noteworthy, fact
which is not still very well understood. Some have argued that this
phenomenonmay arise from an association of physical, chemical or
biological properties of the drug, together with its low half-life or
ability to sterilise the parasite’s gametocytes [9]. Since 1961, PQ is
known to elicit some resistance from asexual blood stages of
P. vivax, but such is of no clinical consequence [20]. Some clinical
evidences of PQ resistance are occasionally reported, but their
detection is rare. In the last two decades, some accounts concerning
relapses of vivax malaria shortly after PQ therapy were registered
essentially in theWestern Pacific, Southeast Asia, India, Central and
South America [121]. Notwithstanding, the frequency, intensity and
distribution of those isolated registers do not seem alarming.2.2. Methemoglobinemia
One of the most relevant adverse effects of PQ, and of other
8AQs, is methemoglobinemia. This is a pathological condition
arising from abnormal accumulation of methemoglobin (MetHgb),
the auto-oxidation product of the hemoglobin iron core.
Oxyhemoglobin, Hgb(Fe(II))O2 is a very stable molecule that
undergoes slow auto-oxidation at a daily rate of about 3%. The
oxidation generates methemoglobin, MetHb [or Hgb(Fe(III))], and
the superoxide radical [122]. The superoxide undergoes dis-
mutation to oxygen and hydrogen peroxide, which is rapidly
decomposed by catalase but some of it reacts with Hgb(Fe(II))O2 to
produce ferrylhemoglobin, Hgb(Fe(IV))]O that bears a rhombic
heme and is difficult to find in vivo since it is rapidly transformed
into Hgb(Fe(III))O2 upon further reaction with Hgb(Fe(II))O2.
The formation of Fe3þ-methemoglobin is favoured under adverse
situations such as oxidative stress, infection, glucose-6-phosphate
dehydrogenase deficiency or influence of xenobiotics. This leads to
an increase ofMetHb concentration in thebody,which implies a high
health risk, such as (i) O2 cannot bind the oxidised iron of theMetHb
heme, thus MetHb cannot transport O2 to the different tissues;
(ii) when one or more subunits have their heme iron oxidised or
attached to CO, the protein quaternary structure is changed and the
affinity of the remaining non-oxidised heme groups towards O2 is
increased, implying a less favoured dissociation of O2 from the heme
groups, thus also compromising oxygen delivery to tissues [123].
Practically almost all 8AQs, including PQ and several of its
metabolites, induce MetHb formation at a rate and extension
higher than usual [124]. Methemoglobinemia usually occurs with
therapeutic or prophylactic dosing regimens. Cyanosis can occur
when the MetHb level exceeds 15–20 g/L in the blood (w10% of the
normal hemoglobin level), although cyanosis may be seen in fair-
skinned persons at MetHb levels below 6% [14]. Additionally,
persons who are deficient of the enzyme NADH methemoglobin
reductase are extremely sensitive to hemoglobin-oxidizing drugs
such as PQ. Fortunately, this enzymatic deficiency is rare [14].
Carboxyprimaquine
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Scheme 1. Main PQ direct metabolites, according to in vitro and in vivo studies.
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As referred previously, PQ is not significantly active against
blood stages of Plasmodium lifecycle [125]. However, it affects the
host erythrocytes, especially in persons with deficiency of glucose-
6-phosphate dehydrogenase (G6PD), towhom PQ causes hemolytic
anemia. In persons with normal levels of G6PD, hemolysis is not
observed. The severity of hemolytic anemia seems to be related
with PQ dosing and the degree of G6PD deficiency [14]. This serious
side effect of PQ and other 8AQs has been reported over half
a century ago [126–130] and has long been known to be due to
intra-erythrocytic oxidative stress mediated by redox-active
metabolites [131], as occurs in methemoglobinemia. Thus, the
major side effects of PQ and other 8AQs are related to the toxicity of
some of their metabolites. For example, 5-hydroxyprimaquine
causes hemolytic anemia and generates reactive oxygen species
(ROS), though it was not associated to lipid peroxidation or alter-
ation of phosphatidylserine asymmetry. These observations are
consistent with damage of cytoskeletal proteins, in the form of
disulfide-linked hemoglobin adducts, leading to disruption and
removal of affected erythrocytes [131].2
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Scheme 2. Proposed pathways for side-chain m2.4. Gastrointestinal effects
Abdominal pain and cramps are commonly reported when PQ is
taken on an empty stomach [132]. About 10–12% of persons
receiving 22.5–30 mg of PQ per day presented mild to moderate
abdominal cramps [133]. Administration of 240 mg/day resulted in
moderate to intolerably severe abdominal cramps and these higher
doses also caused nausea and occasional vomiting. Mild diarrhoea
has also been occasionally reported [14,132]. On the other hand,
food intake was seen to increase the oral bioavailability of PQ,
eventually leading to higher anti-malarial efficacy.2.5. Other adverse effects
Other serious side effects associated with PQ are practically inex-
istent. Psychomotoralterationsdue toPQ-based therapieswerenever
registered,whereas neuropsychiatric side effects are very rare. To our
best knowledge, only a single case of depression and psychosis after
PQ administration was described so far [14]. Also, Schlossberg
reportedan isolateddepressionepisode inapatientwhoafter therapy
with PQ presented mental confusion and hallucinations [134].
No other adverse effects of PQ have been noteworthy, even at
overdosing. Only three reports of PQ overdose cases could be
traced, and side effects observed were a consequence of methe-
moglobinemia [132].
Administration of lethal doses of PQ to experimental animals led
to the appearance of cardiac lesions, but this effect has never been
detected in humans [135]. In fact, though PQ blocks the inward
sodium current INa, slowing the upstroke of the action potential
[108,136], the limited available evidence does not suggest signifi-
cant cardiovascular toxicity [137].3. Relevant primaquine metabolites
PQ is rapidly absorbed in the gastrointestinal tract and
concentrated in the liver, brain, heart, lungs and skeletal muscle.
Themean volume of distribution is 3 L/kg. It peaks in plasmawithin
1–3 h, at w70 mg/mL, and is rapidly excreted in urine, with
a plasma half-life of 4–9 h [9]. PQ is primarily metabolised to5
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N. Vale et al. / European Journal of Medicinal Chemistry 44 (2009) 937–953944carboxyprimaquine that is not accumulated in the body. PQ is also
metabolised to a number of other identified and unidentified
metabolites that are detectable in urine and plasma (Scheme 1).
Onlyw1–4% of PQ is eliminated as the parent compound in urine
[14].3.1. Carboxyprimaquine
Metabolic transformations independent of cytochrome P450
apparently play a role in PQ clearance from the body. The side
chain of PQ undergoes biotransformation to PQ-aldehyde (5,
Scheme 2) in cell-free media containing an oxidase. PQ-aldehyde is
then converted to carboxyprimaquine (6) by an aldehyde dehy-
drogenase. Alternatively, alcohol dehydrogenase may convert PQ
to PQ alcohol (7) [96,138]. Carboxyprimaquine (6) is the main
metabolite of PQ and was identified in mice, monkeys and humans
[139–145]. PQ is rapidly converted into 6 and the peak levels are
reached within 3–12 h post-dose, attaining 1427307 ng/mL,8
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O O10-fold higher than those of the parent drug. Carboxyprimaquine
has not been detected in urine, suggesting that it suffers additional
metabolic transformations before excretion [141]. Carbox-
yprimaquine exhibits schizontocidal activity only at 50 mg/L
(schizontocidal activity), being substantially less active than PQ,
which indicates that an ionisable amino group in the aliphatic
moiety of the drug is an essential structural feature for activity
[144]. On the other hand, the toxicity of carboxyprimaquine in
terms of MetHb formation is lower than that of the parent drug
[141]. Experiments to determine differences between PQ isomers
in terms of their transformation into the correspondingcarboxyprimaquine isomers have shown that the conversion is
faster for ()-PQ than for (þ)-PQ, which may explain the reason
why ()-PQ is less toxic than (þ)-PQ [99].3.2. Hydroxylated species
Metabolic hydroxylation of PQ represents an important role
in the toxicity associated with its therapeutic use. The most
representative hydroxylated metabolite is 5-hydroxyprimaquine
(5-HPQ, 8) [146–153]. According to Bowman et al. [146], this
metabolite induced methemoglobin formation and depletion of
glutathione (GSH), when incubated with suspensions of rat
erythrocytes. Data from this same work indicate that 5-HPQ has
the requisite properties associated with the hematoxicity of PQ.
Other study demonstrated that spleen macrophages play
a crucial role in the removal of 5-HPQ-treated rat erythrocytes from
the circulation, reinforcing that 5-HPQ is an important contributor
to the hemolytic response induced by PQ [147].Hydrogen peroxide is the ultimate oxidant formed from 5-HPQ
by redox-cycling of the corresponding quinone-imine derivative
[148]. Another study evidenced that a double mechanism to
oxyhemoglobin oxidation and the reduced glutathione (GSH) occurs
by autoxidation of the 5-hydroxy-8-aminoquinolines and their
coupled oxidationwith oxyhemoglobin [149]. This phenomenon not
only applies to 5-HPQ but also to other 5-hydroxylated metabolites
such as 5,6-dihydroxyprimaquine (10), 6-methoxy-5-hydroxy-8-
aminoquinoline (11) and 5,6-dihydroxy-8-aminoquinoline (12).
These oxidative processes yield free radicals, superoxide radical
anions, hydrogen peroxide and, ultimately, methemoglobin [149].
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N. Vale et al. / European Journal of Medicinal Chemistry 44 (2009) 937–953 945The formation of hydrogen peroxide, quinone-imine metabo-
lites, drug-derived free radicals and hydroxyl radicals were
demonstrated in another study with 5-HPQ (8), 5,6-dihydroxy-8-
aminoquinoline (12) and 5,6-dihydroxyprimaquine (10) [148,150].
Metabolic incubation of this latter compound, under alkaline
conditions and in the presence of organic solvents and light, has
been reported to yield a three-ring quinine-imine blue product (16)
that would exist in equilibrium with the orthoquinoid form (17,
Scheme 3) [151].
Other hydroxylatedmetabolites of PQ, potentially able to induce
MetHb formation, are 6-desmethylprimaquine (9) and 4-hydrox-
yprimaquine (15), but these are formed in lower amounts than
those of the aforementioned hydroxylated metabolites [152].
Finally, formation of N8-hydroxyprimaquine (14) metabolite has
also been proposed, but comparison of the metabolite alleged to be
14 with synthetic N8-hydroxyprimaquine failed to confirm the
hypothesis [153].
3.3. 6-Methoxy-8-aminoquinoline or MAQ
6-Methoxy-8-aminoquinoline (MAQ, 18) is thoroughly refer-
enced in works devoted to PQ metabolism [148,151–155]. MAQ is
not very active in inducing MetHb formation, thus shows lower
toxicity indices as compared to other PQ metabolites [148,152,153].
However, an early report of Bolchoz et al. described that, when
MAQ was incubated with rat and human liver microsomes, a single
metabolite of MAQwas detected and identified as 6-methoxy-8-(N-
hydroxy)aminoquinoline (MAQ-NOH, 19). This compound was
responsible for causing hemolysis in vivo as well as for inducing the
formation of MetHb when incubated with suspensions of rat
erythrocytes [154]. One year later, the same authors demonstrated
that, under hemolytic conditions, MAQ-NOH generates three
oxygen-active species in rat erythrocytes: hydroxyl radical,
hydrogen peroxide and ferryl heme, responsible for hemolytic
anemia [155].N
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To better understand PQ metabolism, PQ degradation by
microbial enzymes was studied and two new dimeric metabolites
of PQ (20, 21) were identified [156,157]. These dimers of N-acetyl-
primaquinewere inactive in vitro as anti-malarials, thus reinforcing
the idea that the free primary amino group on the aliphatic chain of
PQ is essential for anti-malarial activity [156,157]. Peroxodisulfate
oxidation of PQ has also been shown to produce dimeric derivatives
of the unacetylated drug (22, 23), both of which were active as
schizontocides [158]. Moreover, compound 22 was found to have
a gametocytocidal activity superior to that of PQ, whereas
compound 23 was significantly less active [158].3.5. Sulfur compounds
In addition to N-acetyl PQ dimers 20 and 21 isolated in
microbial metabolism studies, a sulfur-bridged dimer (24) anda thio-quinone-imine metabolite (25) were also proposed on the
basis of spectral and chemical data [159]. The relevance of this
discovery relies on what can be the sulfur source for in vivo
formation of these metabolites, with glutathione being one of the
hypothesized sources [159].3.6. Other compounds
Some microbial metabolism studies confirmed the formation of
N-acetylprimaquine (26) metabolite [139,140,156], but this has not
been detected in human plasma or urine [141]. Metabolic
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Scheme 3. Conversion of the hydroxylated metabolite 10 into a three-ring quinine-
imine blue product (16) in equilibrium with its orthoquinoid form (17) [151].
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urethane [139,140] and amide (28), with a terminal urea, [140,156]
has also been detected.
Other PQ metabolites have been described, such as compound
29 that is formed by peroxodisulfate oxidation of PQ. Biologic
studies have revealed that this PQ derivative can be a novel anti-
malarial with good gametocytocidal activity [158].26
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There have been two main routes for the direct modification of
PQ, on the basis of its most representative metabolictransformations. Therefore, introduction of substituents on the
quinoline ring and modification of the terminal primary amino
group have been the main targets for PQ modification and only
these will be referred to in some detail.
4.1. Modifications at the quinoline ring
Over the last six decades, one of the strategies aimed at
improving the therapeutic efficacy of PQ while reducing its toxicity
has been the introduction of substituent groups at positions 2, 3, 4,
5 and 7 of the quinolinic ring [160]. This produced almost 200 PQ
derivatives (Tables 2–4) bearing diverse groups in one or more
given positions of the ring [6,46,161–179]. Globally, the most
favourable substituent insertions towards anti-malarial activity
where those of methyl groups at positions 4 and 2, tert-butyl at
position 2, simultaneous insertion of ethyl substituents at positions
2 and 4 and pentyloxy at position 5, as well as insertion at position
5 of alkoxy, fluoro, and 3- or 4-substituted phenoxy groups [51,163].
Many of these compounds present activity comparable or superior
to that of PQ both as gametocytocide and schizontocide, as further
described below.
2-Ethyl- and 4-methylprimaquines were evaluated against P.
cynomolgi in rhesus monkeys, where they were as active as the
parent drug [162]. 4-Methylprimaquine was approximately twice
as active as PQ in test animals, with 8/12 cures at a dose of
0.25 mg/kg against P. cynomolgi in infected rhesus monkeys, being
apparently less toxic. However, other alkyl groups inserted at the
quinoline’s C-4 led to the loss of radical curative anti-malarial
activity, even though they were also somewhat less toxic than PQ
[169,171]. These findings led to the synthesis of several derivatives
from 4-methylprimaquine, for instance, by introduction of aryloxy
groups at position 5. The compounds were not only significantly
superior to PQ as radical curative agents, but were also highly
effective as suppressive agents [172]. Compounds 128a and 129a
(Table 3) were significantly effective against established Pneu-
mocystis carinii infections in the rat model when administered
intraperitoneally or orally [46]. Insertion of alkoxy instead ofaryloxy substituents in position 5 of 4-methylprimaquine gener-
ally produced a very pronounced increase in activity at the lower
half of the dosage range, without diminishing toxicity at higher
doses [174].
Table 2
PQ derivatives obtained by substitution at positions 2 and 3 of the quinoline ring
Ring
position
No. Substituent group(s) References
2 1a –OCH3 [161,163]
2a –NH2 [161,163]
3a –N(CH3)2 [161]
4a –Cl [161,163]
5a –C2H5 [161,163]
6a –CH]CH2 [161]
7a –CH2H5, –CH3 (pos. 4) [162]
8a –CH]CH2, –CH3 (pos. 4) [162]
9a –CH3, –C2H5 (pos. 4) [162]
10a –CH3 [163]
11a –CF3 [163]
12a –CH2OH [163]
13a –C6H4(4-Cl) [163]
14a –OCH2–Ph [163]
15a –OCH2–C6H4(4-OCH3) [163]
16a –OCH2–C6H4(4-F) [163]
17a –OCH2–C6H4(4-CF3) [163]
18a –OCH2–C6H4(3-CF3) [163]
19a –OCH2–C6H4(4-Cl) [163]
20a –OCH2–C6H3(2,4-Cl2) [163]
21a –CH]CH–C6H4(4-Cl) [163]
22a –SCH2–Ph [163]
23a –SCH2–C6H4(4-Cl) [163]
24a –CH3, –CH3 (pos. 4) [163]
25a –CH3, –O–C6H4(4-Cl) (pos. 4) [163]
26a –CH3, –CH3 (pos. 5) [163]
27a –CH3, –F (pos. 5) [163]
28a –CH3, –O–C6H4(4-Cl) (pos. 5) [163]
29a –CH3, –O–C6H4(4-F) (pos. 5) [163]
30a –CH3, –O–C6H4(3-CF3) (pos. 5) [163]
31a –CH3, –S–C6H4(4-Cl) (pos. 5) [163]
32a –CH(CH3)2 [164]
33a –CH(CH3)2, –CH(CH3)2 (pos. 5) [164]
34a -c-C5H9 [164]
35a -c-C5H9, -c-C5H9 (pos. 5) [164]
36a -c-C6H11 [164]
37a -c-C6H11, -c-C6H11 (pos. 5) [164]
38a –CH(CH3)2, –OCH3 (pos. 5) [164]
39a –C(CH3)3, –OCH3 (Pos. 5) [164]
40a -c-C6H11, –OCH3 (pos. 5) [164]
41a –C(CH3)3 [164,165,167]
42a -1-adamantyl [165]
43a –C(CH3)3, –O–C6H4(3-CF3) (pos. 5) [167]
44a –C(CH3)3, –CH3 (pos.4), –O–C6H4(3-CF3) (pos. 5) [167]
45a –C(CH3)3, –C2H5 (pos.4), –O–C6H4(3-CF3) (pos. 5) [167]
46a –CH3, –O–(n-C6H13) (pos. 5) [165]
47a –CH3, –CH3 (pos. 4), –O–(n-C6H13) (pos. 5) [165]
48a –OCH3, –CH3 (pos. 4), –O–C6H4(3-CF3) (pos. 5) [167]
49a –O–C6H4(4-Cl), –CH3 (pos. 4), –O–C6H4(3-CF3)
(pos. 5)
[167]
50a –OCH2–C6H4(4-Cl), –CH3 (pos. 4), –O–C6H4(3-CF3)
(Pos. 5)
[167]
51a –OH, –CH3 (pos. 4), –O–C6H4(3-CF3) (pos. 5) [167,175]
52a –OCH3, –CH3 (pos. 4) [167]
53a –OCH3, –CH3 (pos. 4), –O–(CH2)5CH3 (pos. 5) [167]
54a –OCH3, –CH3 (pos. 4), –OCH2–C6H4(3-CF3) (pos. 5) [167]
3 55a –CH3 [163,174]
56a –CH3, –CH3 (pos. 4) [163]
57a –CH3, –O–C6H3(3-CF3, 4-F) (pos. 5) [168]
58a –CH3, –O–(n-C6H13) (pos. 5) [174]
59a –CH3, –O–(2-C6H12) (pos. 5) [174]
60a –CH3, –O–(3-C6H12) (pos. 5) [174]
Table 3
PQ derivatives obtained by substitution at position 4 of the quinoline ring
Ring position No. Substituent group(s) References
4 61a –CH3 [169,170,174]
62a –CH2OH [163]
63a –CH]CH2 [163,171,173]
64a –(CH2)2CH3 [163]
65a –CH]CHCH3 [163]
66a –(CH2)3CH3 [163]
67a –CH]CHC2H5 [163]
68a –CH2CH(CH3)C2H5 [163]
69a –CH2–C6H11 [163]
70a –(CH2)3–C6H11 [163]
71a –(CH2)2–C6H4(4-Cl) [163]
72a –CH]CH–C6H4(4-Cl) [163]
73a –CH]CH–C6H4(3-Cl) [163]
74a –(CH2)2S–C6H4(4-F) [163,171]
75a –CF3 [163]
76a –OH [163]
77a –OCH3 [163,169]
78a –O–C6H4(4-Cl) [163,169]
79a –O–C6H4(4-OCH3) [163,169]
80a –O–CH2–C6H4(4-Cl) [163,169]
81a –SCH3 [163,169]
82a –S–C6H4(4-Cl) [163,169]
83a –S–C6H4(4-OCH3) [163,169]
84a –NH2 [163,169]
85a –NHCH3 [163,169]
86a –NH–C6H4(4-Cl) [163,169]
87a –CH3, –OCH3 (pos. 5) [163,173]
88a –CH3, –O–C6H4(3-CF3) (pos. 5) [163,172]
89a –CH3, –F (pos. 5) [163]
90a –CH3, –Cl (pos. 5) [163]
91a –CH3, –O–C6H5 (pos. 5) [168]
92a –CH3, –O–C6H3(3,5-(CF3)2) (pos. 5) [168]
93a –CH3, –O–C6H3(3-CF3, 4-F) (pos. 5) [168]
94a –O–C6H3(3,4-Cl2) [169]
95a –O–C6H4(3-CF3) [169]
96a –NHC(O)CH3 [169]
97a –(CH2)2S–C6H4(4-OCH3) [171]
98a –(CH2)2S–C6H4(4-Cl) [171]
99a –CH2CH3 [171]
100a –CH3, –O–C6H3(2,4-Cl2) (pos. 5) [172]
101a –CH3, –O–C6H3(3,4-Cl2) (pos. 5) [172]
102a –CH3, –O–C6H4(4-OCH3) (pos. 5) [172]
103a –CH3, –O–C6H4(4-F) (pos. 5) [172]
104a –CH2OCH3, –O–C6H4(3-CF3) (pos. 5) [173]
105a –CH]CH2, –O–CH3 (pos. 5) [173]
106a –CH2O–C6H4(3-CF3), –OCH3 (pos. 5) [173]
107a –CH2O–C6H4(3-CF3), –O–C6H4(3-CF3) [173]
108a –CH3, –O–(n-C3H7) (pos. 5) [174]
109a –CH3, –O–(n-C4H9) (pos. 5) [174]
110a –CH3, –O–(n-C5H11) (pos. 5) [174]
111a –CH3, –O–(n-C6H12) (pos. 5) [174]
112a –CH3, –O–(n-C7H15) (pos. 5) [174]
113a –CH3, –O–(n-C8H17) (pos. 5) [174]
114a –CH3, –O–(n-C9H19) (pos. 5) [174]
115a –CH3, –O–(n-C10H21) (pos. 5) [174]
116a –CH3, –O–(n-C11H23) (pos. 5) [174]
117a –CH3, –O–(n-C12H25) (pos. 5) [174]
118a –CH3, –O–(CH2)4–OPh (pos. 5) [174]
119a –CH3, –O–(CH2)6–OPh (pos. 5) [174]
120a –CH3, –O–(CH2)8–OPh (pos. 5) [174]
121a –CH3, –O–CH2C6H11 (pos. 5) [174]
122a –CH3, –O–C5H9 (pos. 5) [174]
123a –CH3, –O–(CH2)2CH3 (pos. 5) [174]
124a –CH3, –O–(CH2)2–O–(CH2)8CH3 (pos. 5) [174]
125a –CH3, –O–(CH2)6–O–CH3 (pos. 5) [174]
126a –CH3, –O–(CH2)6–O–CH2Ph (pos. 5) [174]
127a –CH3, –O–CH3 (pos. 5) [174]
128a –CH3, –O–C6H4(4-O–C2H5) (pos. 5) [46]
129a –CH3, –O–C6H4–O–(n-C7H15) (pos. 5) [46]
130a –CH3, –O–C6H4–O–(n-C16H33) (pos. 5) [46]
131a –C2H5, –O–C3H7 (pos. 5) [176,177]
132a –C2H5, –O–C4H9 (pos. 5) [176,177]
133a –C2H5, –O–C5H11 (pos. 5) [176,177]
134a –C2H5, –O–C6H13 (pos. 5) [176,177]
135a –C2H5, –O–C7H15 (pos. 5) [176,177]
136a –C2H5, –O–C8H17 (pos. 5) [176,177]
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reasonably active, some of them having lower toxicity than PQ. Also
in this case, introduction of a methyl group on C-3 or C-4 of several
5-phenoxyprimaquines drastically increased the blood-schizo-
ntocidal activity [168].
Recently, 2-tert-butylprimaquine was presented to the scientific
community as being the first 8AQ completely devoid of MetHb
toxicity, possibly through blockade of a relevant degradation
Table 4
PQ derivatives obtained by substituent insertion at positions 5 and 7 of the quinoline
ring
Ring position No. Substituent group(s) References
5 137a –O–CH3 [6,163,179]
138a –O–C2H5 [163]
139a –O–C6H4(4-Cl) [163,168,178]
140a –O–C6H4(4-F) [163,168,178]
141a –O–C6H4(3-CF3) [163,168]
142a –O–C6H4(4-NHCOCH3) [163,178]
143a –COCF3 [163]
144a –Cl [163]
145a –Br [163]
146a –SCH3 [163]
147a –SC6H4(4-Cl) [163]
148a –SC6H4(3-Cl) [163]
149a –SC6H4(2-Cl) [163]
150a –SC6H3(3,4-Cl2) [163]
151a –SC6H3(2,5-Cl2) [163]
152a –SC6H3(3-CF3) [163]
153a –S–C10H7 [163]
154a –NH–C6H4(3-CF3) [163]
155a –N(CH3)2 [163]
156a –O–C6H4(4-OCF3) [168]
157a –O–C6H4(4-OCH3) [168]
158a –O–C6H3(2,4-Cl2) [168]
159a –O–C6H3(3,4-Cl2) [168]
160a –O–C6H3(3,5-(CF3)2) [168]
161a –O–C6H3(3-CF3, 4-F) [168]
162a –OPh [168]
163a –C2H5 [174]
164a –n-C3H7 [174]
165a –n-C4H9 [174]
166a –n-C5H11 [174]
167a –n-C6H13 [174]
168a –n-C8H17 [174]
169a –n-C10H21 [174]
170a –OH [179]
7 171a –CH3 [163]
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over, the anti-malarial activity of 2-tert-butylprimaquine was
demonstrated against P. berghei, Plasmodium yoelii nigeriensis (in
vivo) and P. falciparum (in vitro), exhibiting attributes of a new
potent blood-schizontocidal. These are remarkable findings, as PQ
itself is not a blood-schizontocide [165]. A latest report upholds that
the remarkable blood-schizontocidal activity of 2-tert-butylpri-
maquine may be due to a disturbance of the heme catabolism
pathways in the malarial parasite. Such effect would be similar to
what occurs with CQ, i.e., inhibition of heme crystallization through
formation of a drug–heme complex, preventing clearance of heme-
associated toxicity from the parasite [166]. These were also pre-
sented by Jain et al. studies involving several 8AQ compounds
obtained by insertion of substituents at the quinolinic ring of PQ
[167], where 4-ethyl-5-pentyloxyprimaquine has also displayed
promising results [51].
Overall, it seems that insertion of an appropriate substituent at
the quinoline’s carbon 2 leads to a small improvement in anti-
malarial activity along with a decrease in general systemic toxicity.
In contrast, introduction of a methyl group at C-4 increases thera-
peutic activity, but at the expense of greater toxicity, as concluded
from multiple-dose studies.
The presence of a phenoxy substituent on C-5 decreases toxicity
while maintaining or improving activity. Further efforts that are
focused on combinations of different substitutions on the quinoline
moiety have almost invariably contributed to establish the above as
key modifications towards a good activity/toxicity balance, with
other modifications being less important or only useful for a fine
tuning of the overall compound performance [96].4.2. Modifications at the terminal primary amine
Blocking the terminal primary amine in PQ may represent
a huge improvement in terms of PQ bioavailability, as it can
significantly reduce the extent of PQ conversion into carbox-
yprimaquine. N-Acylation of anti-malarials with amino acids and
oligopeptides has been used in several works aimed at improving
drug transport into malaria-infected erythrocytes and, over the last
two decades, these modifications started to be also seen as a means
to avoid premature PQ inactivation by oxidative deamination to
carboxyprimaquine [180]. An earlier work describes the synthesis
ofN-cysteinyl-primaquine that was subsequently coupled to carrier
proteins, and both the anti-malarial activity in vivo and the acute
lethal toxicity of the protein–drug conjugates were evaluated. The
causal prophylactic activity of the lactosaminated serum albumin
conjugate was two times higher than that of the free drug, whereas
its acute lethal toxicity was at least 6.5-fold lower than that of PQ
[mean lethal dose (LD50)> 85 mg of PQ base/kg]. This yielded
a therapeutic index for the conjugate at least 12 times higher than
that of the free parent drug [181].
Oligopeptide derivatives of PQ such as PQ-Lys-Leu-D-Val, PQ-
Lys-Leu-Ala and PQ-Lys-Leu-L-Val have been prepared and tested
for radical curative anti-malarial activity against P. cynomolgi in
rhesus monkeys and blood-schizontocidal activity against P. berghei
in mice. The D-Val-containing derivative was found to be less toxic
and more active than both its L-Val counterpart and PQ, whereas
the activity of the Ala-bearing compoundwas comparable to that of
the L-Val derivative [182].
PQ N-acylation with amino acids or oligopeptides yields struc-
tures that are amenable to suffer proteolytic degradation; despite
this biorreversibility being desirable in a prodrug, fast conversion
into PQ will not allow overcoming the problems associated with
PQ-based therapies. Thus, additional protection of the peptide
moiety in peptidyl-PQ compounds became a new goal, so that
structures could be obtained with (i) resistance to early proteolytic
cleavage, and (ii) biorreversibility at target tissues or cells in order
to release the active molecule [183].
Borissova et al. synthesized two groups of tetrapeptides with
general formula PQ-Y-Ala-Leu-X-NH2. In the first group, Leu, Tyr,
Lys and Asp were used in the Y positions, while X was Ala. In the
second group, Ala, Tyr, Lys and Asp were used in X positions,
while Y was Leu. All the peptide derivatives were then coupled to
polyacryl starch microparticles (via the N-terminal amino acid a-
amino group), forming lysosomotropic drug carriers [184]. The
same authors studied the importance of enzymes, other than
aminopeptidases, during lysosomal degradation of these conju-
gates, concluding that the latter are substrates for mono-, dia-
mino- and endopeptidases, whereas PQ could not be directly
cleaved by the action of any carboxypeptidase-like enzymes
[185].
Dipeptide derivatives of PQ (PQ-Arg-Phe, PQ-Arg-Lys and PQ-
Ala-Phe) were also synthesized and tested against Chagas disease.
PQ-Arg-Lys was seen to be active against T. cruzi development
inside host cells, probably by interfering with the initial steps of
trypomastigote–amastigote transformation. This derivative was
more active than the other two, so it seems that specific cleavage
has an important role in PQ release [186].
Portela et al. have also evaluated the dipeptide derivatives of PQ
as novel transmission-blocking anti-malarials. In contrast with PQ,
none of the compounds were able to block oocyst production in
mosquitoes’ midguts at 3.75 mg/kg, but all of them were found to
completely inhibit the formation of oocysts at 15 mg/kg, whereas
N-acetylprimaquine is not active at this dose. As a whole, this work
has demonstrated that acylation of the PQ’s primary amino group
effectively prevents the early conversion of PQ into carbox-
yprimaquine, while confirming that the presence of a terminal
NN
HN
NH2
O
R
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gametocytocidal activity [187].
Recently, Gomes et al. worked on the further transformation of
the amino acid moiety linked to the PQ’s primary amine, upon
introduction of an imidazolidin-4-one ring at the amino acid’s a-
amino group (30). Condensation of the N-aminoacyl derivatives of
PQ with carbonyl compounds (ketones or aldehydes) was seen by
these authors as a means to protect the amino acid moiety against
premature proteolytic degradation [188,189].N
O
HN
N
N
H
O
R2
R3
R1
30
31
orImidazolidin-4-ones were highly stable in human plasma, with
a weak or null degree of PQ release after 3 days of incubation.
Moreover, compound 30 hydrolyzed 50–100 times slower in
aqueous buffer at physiological pH and T than the corresponding
imidazolidin-4-ones derived fromdi- and penta-peptides [190,191].
These imidazolidin-4-ones (30) were effective in preventing P.
bergheimalaria transmission fromBalbCmice toAnopheles stephensi
mosquitoes [190,192]. Most of these compounds were also active
against Pneumocystis carinii above 10 mg/mL, which was correlated
to their anti-P. falciparum blood-schizontocidal activity in vitro
[193]. A latest report from the same authors accounts for the
synthesis and biological activity ofN1-aminoacyl derivatives of 30 as
mimetics of PQProXaa structures (where Xaa stands for a general
amino acid linked to proline that, in turn, is linked to the parent
drug). Such structures were again found to be remarkably stable,
modestly active as a blood-schizontocidal against a CQ-resistant
strain of P. falciparum and effective inhibitors of the sporogonic cycle
of P. berghei in A. stephensi mosquitoes [194].
Another example of PQ modification at its primary amino group
concerns its linkage to statine-based inhibitors of Plasmepsin II
(PLM II), aiming at the development of ‘double-drugs’. PLM II is one
of the aspartate proteases involved in the degradation of hemo-
globin during the intra-erythrocytic cycle of P. falciparum. Results in
vitro have shown the above approach to constitute an improve-
ment compared to other statine-based PLM II inhibitors [195].
The development of PQ prodrugs based on PQ modification at
its N-terminus has also been invoked in a work where succinyl-
primaquine and maleylprimaquine derivatives were prepared and
submitted to electrochemical studies. Molecular modification
contributed to facilitate the drug electro-oxidation, but no bio-
logical assays of these potential prodrugs have been described
[196].
Novel PQ derivatives of N-alkyl-, cycloalkyl- or aryl-urea were
also prepared by aminolysis of benzotriazolide with the corre-
sponding amines. The pyridine derivative exhibited the best cyto-
static activities against colon carcinoma, human T-lymphocytes and
murine leukemia, showing also rather marked cytotoxicity towards
human normal fibroblasts. Results of broad antiviral evaluation
showed that pyridine and phenethyl derivatives of urea exhibited
some selective inhibition against cytomegalovirus [197].
PQ derivatives 31were designed and synthesized by Zhu and co-
workers, who found these compounds to have lower toxicity thanPQ, due to a reduced tendency to produce chemically reactive toxic
metabolites and metabolic intermediates [198]. Some of the
compounds possessed therapeutic indices over 10 times superior to
that of CQ [198].4.3. PQ analogues in preclinical or clinical assays
Both types of PQ modification, i.e., insertion of substituents at
the quinoline ring and modification of the terminal primary amino
group, gave rise to the discovery of highly promising drugs
[199,200]. In this connection, this last section will be devoted to
three PQ derivatives that, given their excellent therapeutic pros-
pects, are now under transition to (NPC 1161C, 32) or already in
advanced phases of clinical assays (bulaquine or elubaquine, 33;
tafenoquine, 34) [160] as anti-malarials, and sitamaquine (35) as
a leishmanicidal and anti-Pneumocystis agent.
4.3.1. NPC 1161C (32)
The scaffold of this compound was synthesized in the early
1980s [172], but only 10 years later was the final succinate salt
obtained. NPC 1161C is seen as a very promising anti-malarial
candidate due to its in vivo oral potency in mice, activity against
both blood and tissue stage parasites, favourable toxicity profile,
long-term action, and utility in both prophylaxis and treatment
models. Metabolites are now being investigated so that physico-
chemical and pharmaceutical profiles can be improved [201,202].
Recent data indicate that NPC1161B (the ()-enantiomer) shows
great potential as a new 8AQ drug with limited toxicity and
enhanced efficacy, as compared to those currently in use or under
development, for the treatment of several parasitic infections [95].
4.3.2. Bulaquine or aablaquine (33)
Bulaquine (CDRI 80/53) is a potent anti-malarial PQ analogue
developed at the Central Drug Research Institute – CDRI – of India
[203–209]. After 7 days of PQ administration, methemoglobin
levels increase from 3.97% to 16.32%, whereas bulaquine-induced
levels under identical conditions range between 2.29% and 3.02%.
Moreover, the extent of hemolysis in G6PD-deficient individuals
caused by bulaquine is not as high as that verified for PQ
[160,204,205].
The pharmacokinetic profile of bulaquine was investigated in
rhesus monkeys infected with P. cynomolgi B., against which the
drug has proven gametocytocidal efficacy. Twenty-four hours after
a single administration of bulaquine at 1.25 mg/kg, oocyst devel-
opment was fully blocked, so the disease was not transmitted to A.
stephensimosquitoes fed on the infected monkeys’ blood. A similar
effect is observed 5 h after administration of a single 3.75 mg/kg
dose. These results show that bulaquine is more potent and exerts
its gametocytocidal activity faster than PQ [209].
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studied in clinical assays. Phase II studies were carried out on 697 P.
vivax-infected patients. These studies have shown similar patterns
of relapse for oral administration, during 5 days, of bulaquine at
25 mg/day and of PQ at 15 mg/day, with the advantage falling on
bulaquine due to its lower toxicity [160,205].
Despite some preclinical pilot pharmacokinetic studies in rats,
rabbits and monkeys have been described as applications to the
validation procedures [206,208,210–213], no report has been pub-
lished to date concerning the complete in vivo pharmacokinetic
profile of bulaquine in various species and linking it to in vitro
studies. Recently, Mehrotra et al. suggested that in vitro protein
binding and red blood cell (RBC) uptake studies should be carried
out at around systemic concentrations obtained from in vivo
studies, so that a realistic insight into the pharmacokinetics of the
drug candidate could be obtained [214].O
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Cl4.3.3. Tafenoquine (34)
Tafenoquine was firstly used in an US Army programme as
a substitute for PQ, and was found to be more effective on radical
cure of vivax malaria relapses, yet did not receive too much
attention by then. This picture changed radically once tafeno-
quine’s potent blood-schizontocidal activity against multidrug-
resistant asexual blood stages of P. falciparum was identified,
leading to reinforcement of preclinical development [4]. When
given orally, tafenoquine is slowly absorbed and metabolized, in
contrast to PQ, having a tmax of 12 h and an elimination half-life of
14 days [215]. This unmistakably turned tafenoquine to be the
most serious candidate to substitute PQ in clinics in the near
future.
An early report revealed the treatment of two acute cases of
malaria with tafenoquine alone (800 mg/day over 3 days), instead
of the conventional combination of chloroquine (1500 mg/day over
3 days) with PQ (420 mg/day over 14 days) [216].
The prophylactic efficacy of tafenoquine was studied in a human
P. falciparum challenge model. After administration of a single
600 mg oral dose, tafenoquine successfully prevented P. falciparum
malaria in 3 of 4 non-immune volunteers [217]. Data obtained in
vitro also revealed that some 8AQ derivatives, among which was
tafenoquine, are active against intra-erythrocytic forms of the
parasite, acting through inhibition of hematin polymerization [218].
The promising performance of tafenoquine gave rise to
a number of additional studies, some of them devoted to explore
different dosages and involve higher numbers of individuals, others
to investigate the effects of combining tafenoquine with other anti-malarials [219–221]. Those studies support that tafenoquine has
the potential to be used in a variety of situations beyond that of
chemoprophylaxis [222]. Monthly tafenoquine was safe, well-
tolerated, and highly effective in preventing P. vivax and multidrug-
resistant P. falciparum malaria in Thai soldiers during 6 months of
prophylaxis [223]. The pharmacokinetics of tafenoquine orally
administered to Thai soldiers has been explored, and the drug
demonstrated as both a useful prophylactic drug or for short-term
radical treatment of vivaxmalaria [224]. Additionally, the drug was
well-tolerated by the patients, being occasionally associated only to
mild gastrointestinal effects [225].
Presently, research focus is being directed towards combina-
tions of tafenoquine with other drugs, namely with CQ. This
combined therapy, administered over 8 weeks, is apparently more
effective than ‘CP’ tablets (with PQ at a dose of 22.5 mg/day) in
preventing further P. vivax relapses [226].Ramharter et al. [221] have also found that the tafenoquine–
artemisinine combination was synergistic in vitro, so this combi-
nationmaybecomean excellentwayof treatingmultidrug-resistant
falciparummalaria.
In view of all the above, tafenoquine really appears to be a most
serious candidate to find its place on the Pharmaceutist’s shelves.
However, potential side effects of tafenoquine, such as methemo-
globinemia and the risk of hemolysis in 6GPD-deficient patients,
have to be fully evaluated [227].
4.3.4. Sitamaquine or WR6026 (35)
Sitamaquine is an 8AQ analogue of PQ that is being developed
for the treatment of visceral leishmaniasis and pneumocystic
pneumonia [228]. This drug is already in clinical assays for the oral
treatment of visceral leishmaniasis [41], with phase II trials in India
and Kenya being quite encouraging [229,230]. Physicochemical
analysis of the interaction of sitamaquine with phospholipid
monolayers and sterols at the air–water interface showed interac-
tions only to occur in the presence of anionic phospholipids. Thus,
electrostatic interactions between the positively charged drug and
the negatively charged headgroups seem to be the initial step of
drug interaction with the protozoan cell surface, after which
hydrophobic interactions between the drug’s aromatic ring and the
phospholipid’s inner core of alkyl chains take place, leading to drug
insertion [43]. So it seems that sitamaquine exerts its anti-proto-
zoan action in a fashion similar to that of antimicrobial peptides,
many of them also reported as promising leishmanicidal agents
[231–233].
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Primaquine may not be the anti-malarial drug with the best
therapeutic profiles [121,234], and several aspects of its biological
action are yet to be discovered. However, primaquine is still the only
transmission-blocking anti-malarial clinically useful and it goes on
being used as the platform for developing novel anti-malarials with
improved efficacy and reduced toxicity [21]. Good safety, tolerance
and efficacy, along with key advantages in dosing requirements,
make PQ an excellent drug for preventing malaria in non-pregnant,
G6PD-normal travellers [235,236]. This will certainly lead, in a near
future, to a totally safe and highly active PQderivative or analogue to
be used against malaria and other parasitic diseases. Being malaria
the top-priority tropical disease for the WHO and a major global
health concern, support must be given to scientists from any
researchfieldwho are devoted to the fight against this disease. From
Medicinal Chemists searching for novel compounds to Molecular
Biologists unveiling the complex meanders of the parasite’s life-
cycle, all have a valuable contribution to give, if theyare supplied the
necessary resources. For instance, new chemotherapy strategies can
be now devised after the recent discovery that gametogenesis in
malaria parasites is mediated by PKG, a cGMP-dependent protein
kinase [237]. The costs inherent to this type of research and to the
subsequent efforts towards novel drugs are considerable and
a number of projects have only succeeded due to public–private
partnerships and due to the generosity of philanthropic organiza-
tions such asWellcome, TheRockefeller Foundation, and theBill and
Melinda Gates Foundation [238].
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